HC Wainwright Initiates Coverage on Arcturus Therapeutics (NASDAQ:ARCT)

HC Wainwright assumed coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $60.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 236.13% from the stock’s previous close.

Other research analysts have also issued reports about the company. Leerink Partners cut their price target on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a report on Friday, August 22nd. Wall Street Zen upgraded Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Canaccord Genuity Group cut their target price on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Scotiabank restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Finally, Citigroup restated a “buy” rating and issued a $49.00 target price (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $50.57.

Arcturus Therapeutics Stock Up 6.5%

Shares of ARCT stock opened at $17.85 on Thursday. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $25.88. The firm has a market cap of $484.72 million, a PE ratio of -8.00 and a beta of 2.39. The stock has a 50 day moving average of $14.93 and a 200-day moving average of $13.39.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.The company had revenue of $28.30 million during the quarter, compared to analyst estimates of $17.64 million. As a group, equities analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Large investors have recently bought and sold shares of the stock. Deutsche Bank AG grew its position in Arcturus Therapeutics by 42.7% in the fourth quarter. Deutsche Bank AG now owns 24,768 shares of the biotechnology company’s stock valued at $420,000 after acquiring an additional 7,417 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Arcturus Therapeutics in the first quarter valued at $244,000. GAMMA Investing LLC grew its position in Arcturus Therapeutics by 3,482.9% in the first quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock valued at $550,000 after acquiring an additional 5,085 shares during the period. Ameriprise Financial Inc. grew its position in Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 883 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Arcturus Therapeutics by 7.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after acquiring an additional 1,279 shares during the period. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.